Zhe-Sheng Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6362085/publications.pdf

Version: 2024-02-01

395 papers	21,330 citations	12322 69 h-index	15249 126 g-index
405 all docs	405 docs citations	405 times ranked	20125 citing authors

#	Article	IF	Citations
1	Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 26-41.	0.8	15
2	Cycloruthenated Selfâ€Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. Advanced Materials, 2022, 34, e2100245.	11.1	23
3	Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting. Drug Discovery Today, 2022, 27, 185-195.	3.2	10
4	Paclitaxel and chemoresistance. , 2022, , 251-267.		1
5	Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy. , 2022, , 269-286.		0
6	Prognostic and Therapeutic Values of Autophagy-related Genes in Triple-negative Breast Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 380-386.	0.8	3
7	Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis. Annals of the Rheumatic Diseases, 2022, 81, 544-555.	0.5	13
8	Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Molecular Cancer, 2022, 21, 12.	7.9	60
9	Podophyllum hexandrum and its active constituents: Novel radioprotectants. Biomedicine and Pharmacotherapy, 2022, 146, 112555.	2.5	8
10	Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, .	0.8	2
11	Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 2022, 12, 2193-2205.	5.7	26
12	Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 3.	3.5	88
13	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin. European Journal of Medicinal Chemistry, 2022, 231, 114155.	2.6	3
14	Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera. Pharmaceutical Research, 2022, 39, 2745-2759.	1.7	19
15	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular Cancer, 2022, 21, 40.	7.9	5
16	Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Molecular Cancer, 2022, 21, 43.	7.9	26
17	Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Molecular Cancer, 2022, 21, 37.	7.9	40
18	Research progress in overcoming ibrutinib drug resistance. Drugs of Today, 2022, 58, 85-94.	0.7	0

#	Article	IF	Citations
19	Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Drugs of Today, 2022, 58, 175-185.	0.7	7
20	Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances. Drugs of Today, 2022, 58, 117-132.	0.7	1
21	m6A modification: recent advances, anticancer targeted drug discovery and beyond. Molecular Cancer, 2022, 21, 52.	7.9	138
22	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Frontiers in Pharmacology, 2022, 13, 843829.	1.6	5
23	Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines. Frontiers in Pharmacology, 2022, 13, 850862.	1.6	16
24	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. Frontiers in Pharmacology, 2022, 13, 843110.	1.6	3
25	Proteomics technologies for cancer liquid biopsies. Molecular Cancer, 2022, 21, 53.	7.9	70
26	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	1.6	7
27	Fiberâ€Optic Theranostics (FOT): Interstitial Fiberâ€Optic Needles for Cancer Sensing and Therapy. Advanced Science, 2022, 9, e2200456.	5.6	23
28	The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents. Frontiers in Pharmacology, 2022, 13, 877706.	1.6	2
29	Mechanism of N-Methyl-N-Nitroso-Urea-Induced Gastric Precancerous Lesions in Mice. Journal of Oncology, 2022, 2022, 1-9.	0.6	1
30	Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges. Frontiers in Oncology, 2022, 12, 867655.	1.3	40
31	Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure. Signal Transduction and Targeted Therapy, 2022, 7, 89.	7.1	2
32	The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances. Frontiers in Oncology, 2022, 12, 869929.	1.3	7
33	Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells. Frontiers in Pharmacology, 2022, 13, 867128.	1.6	4
34	An Ayurgenomics Approach: Prakriti-Based Drug Discovery and Development for Personalized Care. Frontiers in Pharmacology, 2022, 13, 866827.	1.6	6
35	MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: InÂvitro and inÂvivo study. Acta Pharmaceutica Sinica B, 2022, 12, 2609-2618.	5.7	7
36	CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Molecular Cancer, 2022, 21, 103.	7.9	19

#	Article	IF	Citations
37	2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Frontiers in Pharmacology, 2022, 13, 899633.	1.6	19
38	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. Frontiers in Oncology, 2022, 12, 855570.	1.3	1
39	Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 2022, 7, 135.	7.1	494
40	Tisotumab vedotin for the treatment of cervical carcinoma. Drugs of Today, 2022, 58, 213-222.	0.7	8
41	Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer. Molecular Cancer, 2022, 21, 112.	7.9	35
42	Therapeutic implication of carbon monoxide in drug resistant cancers. Biochemical Pharmacology, 2022, 201, 115061.	2.0	4
43	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	5.8	80
44	Quercetin ameliorates oxidative stressâ€'induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats. Biomedicine and Pharmacotherapy, 2022, 151, 113108.	2.5	13
45	ERH Gene and Its Role in Cancer Cells. Frontiers in Oncology, 2022, 12, .	1.3	5
46	PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Molecular Cancer, 2022, 21, .	7.9	12
47	Editorial: Novel Molecular Mechanisms and Innovative Therapeutic Approaches for Age-Associated Diseases. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	0
48	New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resistance Updates, 2022, 64, 100849.	6.5	47
49	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. Protein and Cell, 2021, 12, 586-591.	4.8	18
50	The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy. Drug Discovery Today, 2021, 26, 490-502.	3.2	37
51	Chemical molecularâ€based approach to overcome multidrug resistance in cancer by targeting Pâ€glycoprotein (Pâ€gp). Medicinal Research Reviews, 2021, 41, 525-555.	5.0	150
52	Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation â€" Evaluation of intestinal absorption and anti-cancer activity. Journal of Molecular Liquids, 2021, 327, 114866.	2.3	12
53	The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML. , 2021, , .		0
54	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resistance Updates, 2021, 54, 100743.	6.5	107

#	Article	IF	Citations
55	Tepotinib hydrochloride for the treatment of non-small cell lung cancer. Drugs of Today, 2021, 57, 265.	0.7	5
56	Lurbinectedin for the treatment of small cell lung cancer. Drugs of Today, 2021, 57, 377.	0.7	1
57	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology, 2021, 12, 620874.	1.6	8
58	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences, 2021, 22, 2463.	1.8	10
59	Overexpression of ABCC1 Confers Drug Resistance to Betulin. Frontiers in Oncology, 2021, 11, 640656.	1.3	11
60	Insights on the structureâ€"function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. MedComm, 2021, 2, 221-235.	3.1	7
61	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 652972.	1.8	5
62	The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. Frontiers in Cell and Developmental Biology, 2021, 9, 649434.	1.8	6
63	Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. Frontiers in Cell and Developmental Biology, 2021, 9, 640957.	1.8	9
64	Therapeutic strategies to overcome taxane resistance in cancer. Drug Resistance Updates, 2021, 55, 100754.	6.5	103
65	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. European Journal of Medicinal Chemistry, 2021, 216, 113316.	2.6	15
66	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine and Pharmacotherapy, 2021, 136, 111223.	2.5	12
67	Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. Drug Discovery Today, 2021, 26, 2282-2302.	3.2	17
68	A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. Cancers, 2021, 13, 2565.	1.7	13
69	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 44-53.	0.8	0
70	Natural Product as Substrates of ABC Transporters: A Review. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 222-238.	0.8	9
71	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. Drug Discovery Today, 2021, 26, 1293-1301.	3.2	11
72	AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 680663.	1.3	4

#	Article	IF	Citations
73	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. Frontiers in Public Health, 2021, 9, 671788.	1.3	31
74	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discovery Today, 2021, 26, 1284-1292.	3.2	65
75	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Frontiers in Immunology, 2021, 12, 658519.	2.2	63
76	Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2021, 64, 9120-9140.	2.9	33
77	The role of endolysosomal trafficking in anticancer drug resistance. Drug Resistance Updates, 2021, 57, 100769.	6.5	23
78	Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates, 2021, 57, 100770.	6.5	59
79	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Frontiers in Cell and Developmental Biology, 2021, 9, 697927.	1.8	8
80	Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. Frontiers in Pharmacology, 2021, 12, 720726.	1.6	81
81	Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. Drug Discovery Today, 2021, 26, 1735-1743.	3.2	19
82	Synthesis and anticancer evaluation of sulfur containing 9-anilinoacridines. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, .	0.8	1
83	Recent progress on targeting leukemia stem cells. Drug Discovery Today, 2021, 26, 1904-1913.	3.2	7
84	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	0
85	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Experimental Cell Research, 2021, 405, 112728.	1.2	8
86	CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). Biochemical Pharmacology, 2021, 190, 114652.	2.0	5
87	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	0.7	57
88	Novel nanomedicines to overcome cancer multidrug resistance. Drug Resistance Updates, 2021, 58, 100777.	6.5	93
89	MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Molecular Cancer, 2021, 20, 118.	7.9	24
90	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14895-14911.	2.9	27

#	Article	IF	Citations
91	Application of microfluidic chips in anticancer drug screening. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	4
92	CUL4high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. American Journal of Pathology, 2021, 191, 1638-1650.	1.9	0
93	Drug resistance: from bacteria to cancer. Molecular Biomedicine, 2021, 2, 27.	1.7	14
94	Formulation and characterization of oleic acid magnetic PEG PLGA nanoparticles for targeting glioblastoma multiforme. Journal of Magnetism and Magnetic Materials, 2021, 533, 167970.	1.0	9
95	VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers, 2021, 13, 4675.	1.7	4
96	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	1.3	6
97	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. International Journal of Biological Sciences, 2021, 17, 2652-2665.	2.6	4
98	Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. Drugs of Today, 2021, 57, 621.	0.7	5
99	Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1. Frontiers in Cell and Developmental Biology, 2021, 9, 730309.	1.8	6
100	Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs. Frontiers in Cell and Developmental Biology, 2021, 9, 766371.	1.8	6
101	Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis. Frontiers in Oncology, 2021, 11, 772915.	1.3	18
102	RNA methylation and cancer treatment. Pharmacological Research, 2021, 174, 105937.	3.1	89
103	Double-Coated Poly(butyl Cyanoacrylate) Nanoparticles as a Potential Carrier for Overcoming P-Gp- and BCRP-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Nanotechnology, 2021, 3, .	2.4	5
104	Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. Journal of Medicinal Chemistry, 2021, 64, 16187-16204.	2.9	14
105	Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 374.	3.5	8
106	Reconstruction of intestinal microecology of Type 2 diabetes by Fecal Microbiota Transplantation: Why and How. Bosnian Journal of Basic Medical Sciences, 2021, , .	0.6	11
107	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 17346-17365.	2.9	13
108	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. Frontiers in Pharmacology, 2021, 12, 732403.	1.6	13

#	Article	IF	Citations
109	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm, 2021, 2, 765-777.	3.1	15
110	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates, 2020, 48, 100663.	6.5	180
111	A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. Materials Science and Engineering C, 2020, 107, 110224.	3.8	23
112	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Letters, 2020, 472, 132-141.	3.2	10
113	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates, 2020, 53, 100720.	6.5	107
114	Chloroquine against malaria, cancers and viral diseases. Drug Discovery Today, 2020, 25, 2012-2022.	3.2	61
115	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52
116	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Molecular Cancer, 2020, 19, 147.	7.9	50
117	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry, 2020, 63, 15979-15996.	2.9	25
118	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Frontiers in Pharmacology, 2020, 11, 1208.	1.6	23
119	A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. Molecular Therapy - Oncolytics, 2020, 18, 137-148.	2.0	11
120	Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Frontiers in Microbiology, 2020, 11, 1718.	1.5	8
121	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. Frontiers in Oncology, 2020, 10, 1219.	1.3	11
122	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Molecular Cancer, 2020, 19, 134.	7.9	44
123	Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 865.	1.8	13
124	Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. Frontiers in Oncology, 2020, 10, 1732.	1.3	10
125	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy, 2020, 5, 193.	7.1	66
126	BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 2502.	1.7	11

#	Article	IF	Citations
127	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Frontiers in Cell and Developmental Biology, 2020, 8, 601400.	1.8	18
128	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. Frontiers in Cell and Developmental Biology, 2020, 8, 607275.	1.8	9
129	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Frontiers in Oncology, 2020, 10, 574861.	1.3	16
130	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Frontiers in Oncology, 2020, 10, 674.	1.3	18
131	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. Frontiers in Oncology, 2020, 10, 700.	1.3	25
132	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications, 2020, 40, 285-300.	3.7	24
133	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. Frontiers in Oncology, 2020, 10, 228.	1.3	15
134	Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. Journal of Natural Products, 2020, 83, 1563-1570.	1.5	8
135	Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer, 2020, 19, 54.	7.9	120
136	ABCG2 Overexpression Contributes to Pevonedistat Resistance. Cancers, 2020, 12, 429.	1.7	10
137	Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. Frontiers in Oncology, 2020, 10, 932.	1.3	8
138	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2020, 63, 8157-8178.	2.9	25
139	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. Biochemical Pharmacology, 2020, 175, 113848.	2.0	21
140	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. Experimental Cell Research, 2020, 388, 111858.	1.2	14
141	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers, 2020, 12, 466.	1.7	37
142	Lipidâ€"Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers, 2020, 12, 498.	1.7	5
143	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1387.	1.8	25
144	Recent progress in antitumor functions of the intracellular antibodies. Drug Discovery Today, 2020, 25, 1109-1120.	3.2	9

#	Article	IF	Citations
145	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	1.7	33
146	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resistance Updates, 2020, 49, 100681.	6.5	154
147	The PI3K subunits, P110Î± and P110Î² are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Molecular Cancer, 2020, 19, 10.	7.9	72
148	The combination of disulfiram and copper for cancer treatment. Drug Discovery Today, 2020, 25, 1099-1108.	3.2	95
149	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. Experimental Cell Research, 2020, 391, 111987.	1.2	8
150	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. Journal of Medicinal Chemistry, 2020, 63, 5458-5476.	2.9	27
151	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. Frontiers in Pharmacology, 2020, 11, 615824.	1.6	14
152	Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia. Frontiers in Oncology, 2020, 10, 588641.	1.3	6
153	Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Frontiers in Oncology, 2020, 10, 624954.	1.3	13
154	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resistance Updates, 2020, 52, 100703.	6.5	25
155	Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro. Gastroenterology Report, 2020, 8, 465-475.	0.6	6
156	Dual TTK/CLK2 inhibitor, CCâ€671, selectively antagonizes ABCG2â€mediated multidrug resistance in lung cancer cells. Cancer Science, 2020, 111, 2872-2882.	1.7	24
157	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7. , 2020, , .		2
158	Abstract 3006: Anticancer and multidrug resistance-reversing activities of novel antimicrobial peptides. , 2020, , .		1
159	Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. , 2020, , .		1
160	The targeting of nonâ€coding RNAs by curcumin: Facts and hopes for cancer therapy (Review). Oncology Reports, 2019, 42, 20-34.	1.2	38
161	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1524-1535.	0.5	32
162	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	1.3	29

#	Article	IF	Citations
163	Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. International Journal of Biochemistry and Cell Biology, 2019, 110, 21-28.	1.2	28
164	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 4095.	1.8	19
165	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. European Journal of Pharmacology, 2019, 863, 172611.	1.7	22
166	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 179, 849-862.	2.6	28
167	Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today, 2019, 24, 2086-2095.	3.2	18
168	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2019, 9, 313.	1.3	28
169	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2019, 166, 120-127.	2.0	52
170	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Molecular Pharmacology, 2019, 96, 73-89.	1.0	23
171	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 1-11.		7
172	An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. Chemical Communications, 2019, 55, 3833-3836.	2.2	11
173	From Antimicrobial to Anticancer Peptides: The Transformation of Peptides. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 70-84.	0.8	29
174	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. Future Medicinal Chemistry, 2019, 11, 323-336.	1.1	31
175	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 13-27.		0
176	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Molecular Cancer, 2019, 18, 23.	7.9	149
177	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules, 2019, 24, 4383.	1.7	46
178	Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. International Journal of Molecular Sciences, 2019, 20, 268.	1.8	27
179	The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo. Acta Pharmaceutica Sinica B, 2019, 9, 316-323.	5.7	20
180	Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters, 2019, 442, 91-103.	3.2	41

#	Article	IF	Citations
181	Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer Letters, 2019, 442, 104-112.	3.2	33
182	Discovery of Novel Quinolineâ€"Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. Journal of Medicinal Chemistry, 2019, 62, 993-1013.	2.9	84
183	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters, 2019, 440-441, 82-93.	3.2	83
184	Abstract 3796: Selonsertib, an ASK1 inhibitor, antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Research, 2019, 79, 3796-3796.	0.4	1
185	Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 177-186.	0.8	9
186	Design, synthesis and biological evaluation of selective survivin inhibitors. Journal of Biomedical Research, 2019, 33, 82.	0.7	5
187	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: InÂvitro and inÂvivo. Cancer Letters, 2018, 424, 19-29.	3.2	42
188	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 1515-1528.	1.1	48
189	Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. European Journal of Medicinal Chemistry, 2018, 149, 211-224.	2.6	15
190	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. Journal of Medicinal Chemistry, 2018, 61, 834-864.	2.9	25
191	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters, 2018, 421, 186-198.	3.2	96
192	Oncosis-inducing cyclometalated iridium(<scp>iii</scp>) complexes. Chemical Science, 2018, 9, 5183-5190.	3.7	95
193	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2018, 143, 1535-1542.	2.6	41
194	Patterned synthesis of ZnO nanorod arrays for nanoplasmonic waveguide applications. Optics Communications, 2018, 411, 53-58.	1.0	13
195	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Frontiers in Pharmacology, 2018, 9, 1236.	1.6	41
196	Erratum to â€œDiscovery of a Non-toxic [1,2,4] Triazolo[1,5-A] Pyrimidin-7-One (WS-10) that Modulates ABCB1-Mediated Multidrug Resistance (MDR)â€•[Bioorganic & Medicinal Chemistry 26/18 (2018) 5006â€"5017]. Bioorganic and Medicinal Chemistry, 2018, 26, 5973.	1.4	0
197	Modulating ROS to overcome multidrug resistance in cancer. Drug Resistance Updates, 2018, 41, 1-25.	6.5	420
198	A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. International Journal of Nanomedicine, 2018, Volume 13, 8411-8427.	3.3	19

#	Article	IF	Citations
199	Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Pharmacology, 2018, 9, 1097.	1.6	47
200	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology, 2018, 158, 274-285.	2.0	47
201	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. Journal of Medicinal Chemistry, 2018, 61, 5988-6001.	2.9	53
202	Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). Bioorganic and Medicinal Chemistry, 2018, 26, 5006-5017.	1.4	17
203	Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance. Frontiers in Pharmacology, 2018, 9, 1545.	1.6	11
204	TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 341-347.	0.8	10
205	Icotinib improves progression free survival in epidermal growth factor receptor positive non-small cell lung cancer patients. Translational Cancer Research, 2018, 7, S26-S30.	0.4	0
206	Pharmacotherapeutic Options for Philadelphia Chromosome- Positive CML. Journal of Cancer Research Updates, 2018, 7, 49-58.	0.3	0
207	Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. Pharmacological Research, 2017, 119, 89-98.	3.1	27
208	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. Molecular Cancer Therapeutics, 2017, 16, 1021-1030.	1.9	30
209	GSK1904529A, a Potent IGFâ€IR Inhibitor, Reverses MRP1â€Mediated Multidrug Resistance. Journal of Cellular Biochemistry, 2017, 118, 3260-3267.	1.2	21
210	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. Biochemical Pharmacology, 2017, 132, 29-37.	2.0	28
211	2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. Journal of Cellular Biochemistry, 2017, 118, 2420-2429.	1.2	5
212	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. Journal of Medicinal Chemistry, 2017, 60, 1449-1468.	2.9	93
213	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Scientific Reports, 2017, 7, 42106.	1.6	10
214	Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharmaceutica Sinica B, 2017, 7, 564-570.	5.7	14
215	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacological Research, 2017, 121, 184-193.	3.1	13
216	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: InÂvitro and inÂvivo study. Cancer Letters, 2017, 396, 145-154.	3.2	56

#	Article	IF	Citations
217	Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4832-4837.	1.0	19
218	Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4698-4704.	1.0	19
219	6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. Journal of Natural Products, 2017, 80, 2391-2398.	1.5	29
220	The development of anticancer ruthenium(<scp>ii</scp>) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews, 2017, 46, 5771-5804.	18.7	793
221	Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer, 2017, 36, 52.	4.9	497
222	Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer Letters, 2017, 386, 100-109.	3.2	32
223	CDX2 Stimulates the Proliferation of Porcine Intestinal Epithelial Cells by Activating the mTORC1 and Wnt/Î²-Catenin Signaling Pathways. International Journal of Molecular Sciences, 2017, 18, 2447.	1.8	31
224	Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. International Journal of Oncology, 2017, 51, 257-268.	1.4	22
225	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. Oncotarget, 2017, 8, 29760-29770.	0.8	31
226	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget, 2017, 8, 93785-93799.	0.8	22
227	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules, 2016, 21, 1236.	1.7	37
228	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates, 2016, 27, 14-29.	6.5	511
229	Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria. Journal of Medicinal Chemistry, 2016, 59, 5022-5034.	2.9	56
230	TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics, 2016, 8, 651-666.	1.0	72
231	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Letters, 2016, 383, 220-229.	3.2	24
232	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Scientific Reports, 2016, 6, 25694.	1.6	48
233	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NFâ€ÎºB Pathway in Colorectal Cancer. Journal of Cellular Biochemistry, 2016, 117, 1471-1481.	1.2	45
234	Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 281-289.	1.5	20

#	Article	IF	Citations
235	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 255-265.	3.3	122
236	1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors. Cellular Physiology and Biochemistry, 2016, 38, 185-193.	1.1	8
237	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget, 2016, 7, 5877-5891.	0.8	28
238	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. Journal of Biomedical Research, 2016, 30, 120-133.	0.7	13
239	B4G2 Induces Mitochondrial Apoptosis by the ROS-Mediated Opening of Ca2+-Dependent Permeability Transition Pores. Cellular Physiology and Biochemistry, 2015, 37, 838-852.	1.1	17
240	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers, 2015, 7, 2360-2371.	1.7	194
241	Esters of the Marine-Derived Triterpene Sipholenol A Reverse P-GP-Mediated Drug Resistance. Marine Drugs, 2015, 13, 2267-2286.	2.2	18
242	A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDRin vitroandin vivo. Oncotarget, 2015, 6, 39276-39291.	0.8	20
243	Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. Oncotarget, 2015, 6, 24277-24290.	0.8	38
244	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 183-208.	0.1	2
245	Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. International Journal of Oncology, 2015, 46, 2029-2038.	1.4	34
246	Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochemical Pharmacology, 2015, 93, 266-276.	2.0	44
247	The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resistance Updates, 2015, 18, 1-17.	6.5	590
248	ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. Chinese Journal of Cancer, 2015, 34, 115-20.	4.9	17
249	Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS Journal, 2015, 17, 802-812.	2.2	155
250	The reversal of antineoplastic drug resistance in cancer cells by Î²-elemene. Chinese Journal of Cancer, 2015, 34, 488-95.	4.9	28
251	Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. Acta Biomaterialia, 2015, 25, 268-283.	4.1	37
252	Silver nanoparticles: synthesis, properties, and therapeutic applications. Drug Discovery Today, 2015, 20, 595-601.	3.2	723

#	Article	IF	Citations
253	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. , 2015, , 593-619.		0
254	Abstract 4432: A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. , 2015, , .		1
255	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget, 2015, 6, 510-521.	0.8	28
256	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget, 2015, 6, 17738-17752.	0.8	17
257	5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/Î²-catenin/MMP-7 signaling pathway. Oncotarget, 2015, 6, 25975-25987.	0.8	47
258	IKK inhibition increases bortezomib effectiveness in ovarian cancer. Oncotarget, 2015, 6, 26347-26358.	0.8	23
259	Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway. Journal of Cancer Research Updates, 2015, 4, 47-53.	0.3	1
260	Lamellarin O, a Pyrrole Alkaloid from an Australian Marine Sponge, Ianthella sp., Reverses BCRP Mediated Drug Resistance in Cancer Cells. Marine Drugs, 2014, 12, 3818-3837.	2.2	63
261	miR200c Attenuates P-gpâ€"Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer. Molecular Cancer Therapeutics, 2014, 13, 3137-3151.	1.9	74
262	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Future Oncology, 2014, 10, 1827-1841.	1.1	28
263	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers, 2014, 6, 1925-1952.	1.7	60
264	WHI â€P154 enhances the chemotherapeutic effect of anticancer agents in ABCG 2â€overexpressing cells. Cancer Science, 2014, 105, 1071-1078.	1.7	21
265	In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter <scp>MRP1</scp>. British Journal of Pharmacology, 2014, 171, 5845-5857.	2.7	52
266	Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10â€"Mediated Paclitaxel Resistance: A Preclinical Study. Molecular Cancer Therapeutics, 2014, 13, 714-723.	1.9	39
267	Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. European Journal of Pharmacology, 2014, 733, 34-44.	1.7	22
268	Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discovery Today, 2014, 19, 482-488.	3.2	59
269	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. International Journal of Biochemistry and Cell Biology, 2014, 51, 111-119.	1.2	29
270	Fragmented polymer nanotubes from sonication-induced scission with a thermo-responsive gating system for anti-cancer drug delivery. Journal of Materials Chemistry B, 2014, 2, 1327-1334.	2.9	24

#	Article	IF	Citations
271	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical Pharmacology, 2014, 90, 367-378.	2.0	50
272	Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3â€²-azido-3â€²-deoxythymidine as anticancer prodrugs. Bioorganic and Medicinal Chemistry, 2014, 22, 5747-5756.	1.4	5
273	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochemical Pharmacology, 2014, 91, 144-156.	2.0	18
274	Novel Hybrids of Natural Oridonin-Bearing Nitrogen Mustards as Potential Anticancer Drug Candidates. ACS Medicinal Chemistry Letters, 2014, 5, 797-802.	1.3	49
275	Design and Synthesis of Human ABCB1 (P-Glycoprotein) Inhibitors by Peptide Coupling of Diverse Chemical Scaffolds on Carboxyl and Amino Termini of (S)-Valine-Derived Thiazole Amino Acid. Journal of Medicinal Chemistry, 2014, 57, 4058-4072.	2.9	51
276	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Letters, 2014, 350, 61-68.	3.2	35
277	PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharmaceutica Sinica B, 2014, 4, 202-207.	5.7	24
278	ARRYâ€334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATPâ€Binding Cassette Subfamily G Member 2. Journal of Cellular Biochemistry, 2014, 115, 1381-1391.	1.2	18
279	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology, 2014, 89, 52-61.	2.0	47
280	Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 2014, 19, 13848-13877.	1.7	97
281	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese Journal of Cancer, 2014, 33, 223-230.	4.9	48
282	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncology Reports, 2014, 31, 1605-1612.	1.2	26
283	Î²-elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncology Reports, 2014, 31, 858-866.	1.2	47
284	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. International Journal of Oncology, 2014, 44, 1634-1642.	1.4	28
285	Cytokine Detection by Flow Cytometry. Methods in Molecular Biology, 2014, 1172, 235-242.	0.4	11
286	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41
287	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. Journal of Cancer Research Updates, 2014, 3, 169-173.	0.3	1
288	Anticancer Activity of Five Traditionally Used Medicinal Plants' Extracts. Journal of Cancer Research Updates, 2014, 3, .	0.3	1

#	Article	IF	Citations
289	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. Anticancer Research, 2014, 34, 4767-73.	0.5	14
290	Saracatinib (AZD0530) is a potent modulator of ABCB1â€mediated multidrug resistance in vitro and in vivo. International Journal of Cancer, 2013, 132, 224-235.	2.3	37
291	New phenstatinâ€"fatty acid conjugates: Synthesis and evaluation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5119-5122.	1.0	9
292	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochemical Pharmacology, 2013, 85, 514-524.	2.0	80
293	Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Biochemical Pharmacology, 2013, 85, 1257-1268.	2.0	30
294	Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. European Journal of Pharmaceutical Sciences, 2013, 49, 441-450.	1.9	23
295	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 189-199.	1.1	48
296	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Letters, 2013, 328, 307-317.	3.2	106
297	Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. Anti-Cancer Drugs, 2013, 24, 441-454.	0.7	10
298	Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology Reports, 2013, 29, 2479-2485.	1.2	37
299	Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS ONE, 2013, 8, e55576.	1.1	34
300	BBA, a Synthetic Derivative of 23-hydroxybutulinic Acid, Reverses Multidrug Resistance by Inhibiting the Efflux Activity of MRP7 (ABCC10). PLoS ONE, 2013, 8, e74573.	1.1	13
301	Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. Frontiers in Pharmacology, 2013, 4, 82.	1.6	15
302	BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells. PLoS ONE, 2013, 8, e54181.	1.1	22
303	Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). Pakistan Journal of Pharmaceutical Sciences, 2013, 26, 1151-6.	0.2	3
304	Autophagy and Transporter-Based Multi-Drug Resistance. Cells, 2012, 1, 558-575.	1.8	62
305	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Anti-Cancer Drugs, 2012, 23, 865-873.	0.7	23
306	Role of ABC transporters in cancer chemotherapy. Chinese Journal of Cancer, 2012, 31, 51-57.	4.9	103

#	Article	IF	Citations
307	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular Cancer Therapeutics, 2012, 11, 2033-2044.	1.9	81
308	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Research and Treatment, 2012, 135, 737-747.	1.1	95
309	Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Molecular Pharmacology, 2012, 82, 47-58.	1.0	87
310	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates, 2012, 15, 70-80.	6.5	143
311	Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7268-7271.	1.0	18
312	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology, 2012, 84, 766-774.	2.0	22
313	BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistancein Vitroandin Vivo. Molecular Pharmaceutics, 2012, 9, 3147-3159.	2.3	43
314	Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance. Marine Drugs, 2012, 10, 2312-2321.	2.2	61
315	Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202. Molecular Pharmaceutics, 2012, 9, 1971-1982.	2.3	35
316	Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 2012, 31, 58-72.	4.9	217
317	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochemical Pharmacology, 2012, 83, 1613-1622.	2.0	62
318	<scp>PDE</scp>5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (<scp>ATP</scp>â€binding Cassette <scp>C</scp>10) transporter. Cancer Science, 2012, 103, 1531-1537.	1.7	37
319	Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chinese Journal of Cancer, 2012, 31, 110-118.	4.9	60
320	Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Molecular Pharmaceutics, 2011, 8, 1687-1697.	2.3	41
321	Biosynthesis of Nanoparticles by Microorganisms and Their Applications. Journal of Nanomaterials, 2011, 2011, 1-16.	1.5	554
322	The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter. PLoS ONE, 2011, 6, e19329.	1.1	71
323	Editorial [Hot Topic: ABC Transporters in Pharmacology/Physiology and Human Diseases (Guest Editor:) Tj ETQq1 1 0.784314 rgBT /Over	0.9	6
324	Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells. Oncology Letters, 2011, 2, 549-556.	0.8	5

#	Article	IF	Citations
325	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS Journal, 2011, 278, 3226-3245.	2.2	222
326	Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6495-6499.	1.0	6
327	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research, 2011, 71, 3029-3041.	0.4	157
328	Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer. Cancer Research, 2011, 71, 3735-3738.	0.4	57
329	Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10â^'/â^' Mice. Cancer Research, 2011, 71, 3649-3657.	0.4	62
330	Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology, 2011, 12, 570-594.	0.9	185
331	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical Pharmacology, 2010, 79, 154-161.	2.0	89
332	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2010, 80, 1497-1506.	2.0	57
333	The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leukemia Research, 2010, 34, 696-697.	0.4	8
334	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Research, 2010, 34, 1255-1268.	0.4	252
335	Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research, 2010, 70, 7981-7991.	0.4	297
336	Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS ONE, 2009, 4, e7520.	1.1	65
337	Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B. Cancer Research, 2009, 69, 178-184.	0.4	118
338	Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival. Clinical Cancer Research, 2009, 15, 1762-1769.	3.2	73
339	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochemical Pharmacology, 2009, 77, 781-793.	2.0	69
340	Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochemical Pharmacology, 2009, 77, 993-1001.	2.0	66
341	Nilotinib (AMN107, TasignaÂ®) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacology, 2009, 78, 153-161.	2.0	201
342	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology, 2009, 78, 355-364.	2.0	26

#	Article	IF	Citations
343	RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Letters, 2009, 276, 189-195.	3.2	76
344	Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters, 2009, 279, 74-83.	3.2	108
345	Sipholane Triterpenoids: Chemistry, Reversal of ABCB1/P-Glycoprotein-Mediated Multidrug Resistance, and Pharmacophore Modeling. Journal of Natural Products, 2009, 72, 1291-1298.	1.5	51
346	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncology Reports, 2009, 21, 483-9.	1.2	42
347	Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia Research, 2008, 32, 799-809.	0.4	52
348	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research, 2008, 68, 7905-7914.	0.4	362
349	Proteome Analysis of Multidrug Resistance of Human Oral Squamous Carcinoma Cells Using CD147 Silencing. Journal of Proteome Research, 2008, 7, 4784-4791.	1.8	26
350	Correction: Reversal of Multidrug Resistance by Lapatinib. Cancer Research, 2008, 68, 10387-10387.	0.4	7
351	Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. Anti-Cancer Drugs, 2007, 18, 1015-1021.	0.7	2
352	Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Sipholane Triterpenoids. Journal of Natural Products, 2007, 70, 928-931.	1.5	55
353	Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2â€"Mediated Drug Resistance. Cancer Research, 2007, 67, 11012-11020.	0.4	280
354	Sipholenol A, a marineâ€derived sipholane triterpene, potently reverses Pâ€glycoprotein (ABCB1)â€mediated multidrug resistance in cancer cells. Cancer Science, 2007, 98, 1373-1380.	1.7	56
355	ABCC10, ABCC11, and ABCC12. Pflugers Archiv European Journal of Physiology, 2007, 453, 675-684.	1.3	126
356	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncology Reports, 2007, 17, 969-76.	1.2	42
357	Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. Oncology Reports, 2007, 18, 721-7.	1.2	7
358	Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biology and Therapy, 2006, 5, 39-47.	1.5	132
359	Transport of Bile Acids, Sulfated Steroids, Estradiol 17-Î²-d-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11). Molecular Pharmacology, 2005, 67, 545-557.	1.0	146
360	Analysis of the In Vivo Functions of Mrp3. Molecular Pharmacology, 2005, 68, 160-168.	1.0	161

#	Article	IF	Citations
361	Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10). Cancer Research, 2004, 64, 4927-4930.	0.4	195
362	MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2â€²,3â€²-Dideoxycytidine and 9â€²-(2â€²-Phosphonylmethoxyethyl)adenine. Journal of Biological Chemistry, 2003, 278, 29509-29514.	1.6	215
363	Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	167
364	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Research, 2003, 63, 4048-54.	0.4	245
365	Targeted Deletion of Both Thymidine Phosphorylase and Uridine Phosphorylase and Consequent Disorders in Mice. Molecular and Cellular Biology, 2002, 22, 5212-5221.	1.1	55
366	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. Oncology Reports, 2002, 9, 839.	1.2	2
367	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Research, 2002, 62, 3144-50.	0.4	245
368	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. Oncology Reports, 2002, 9, 839-44.	1.2	9
369	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Research, 2002, 62, 6172-7.	0.4	190
370	Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function. International Journal of Cancer, 2001, 93, 107-113.	2.3	59
371	Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance. International Journal of Cancer, 2001, 93, 869-874.	2.3	128
372	MRP subfamily transporters and resistance to anticancer agents. Journal of Bioenergetics and Biomembranes, 2001, 33, 493-501.	1.0	151
373	Reversing Effect of Agosterol A, a Spongean Sterol Acetate, on Multidrug Resistance in Human Carcinoma Cells. Japanese Journal of Cancer Research, 2001, 92, 886-895.	1.7	62
374	Glutathione-dependent Binding of a Photoaffinity Analog of Agosterol A to the C-terminal Half of Human Multidrug Resistance Protein. Journal of Biological Chemistry, 2001, 276, 23197-23206.	1.6	56
375	Transport of Cyclic Nucleotides and Estradiol 17-Î²-d-Glucuronide by Multidrug Resistance Protein 4. Journal of Biological Chemistry, 2001, 276, 33747-33754.	1.6	358
376	Multidrug Resistance Reversal Activity of Taxoids fromTaxus cuspidatein KB-C2 and 2780AD Cells. Japanese Journal of Cancer Research, 2000, 91, 638-642.	1.7	18
377	Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-Benzoylated Taxinine K. Molecular Pharmacology, 2000, 58, 1563-1569.	1.0	27
378	Functional Comparison between YCF1 and MRP1 Expressed in Sf21 Insect Cells. Biochemical and Biophysical Research Communications, 2000, 270, 608-615.	1.0	20

#	Article	IF	Citations
379	Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 Cells. Journal of the National Cancer Institute, 1999, 91, 1647-1653.	3.0	174
380	Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. Tetrahedron, 1999, 55, 13965-13972.	1.0	40
381	An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Letters, 1999, 138, 13-22.	3.2	15
382	Enhanced transport of anticancer agents and leukotriene C4by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Letters, 1999, 456, 327-331.	1.3	141
383	Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion Transporter. Molecular Pharmacology, 1999, 56, 1219-1228.	1.0	165
384	Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp.. Tetrahedron Letters, 1998, 39, 6303-6306.	0.7	63
385	Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Letters, 1998, 129, 69-76.	3.2	28
386	Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Letters, 1998, 130, 175-182.	3.2	32
387	An Active Efflux System for Heavy Metals in Cisplatin-Resistant Human KB Carcinoma Cells. Experimental Cell Research, 1998, 240, 312-320.	1.2	47
388	Reversal of Heavy Metal Resistance in Multidrug-Resistant Human KB Carcinoma Cells. Biochemical and Biophysical Research Communications, 1997, 236, 586-590.	1.0	46
389	Characterization of the ATP-Dependent LTC4Transporter in Cisplatin-Resistant Human KB Cells. Biochemical and Biophysical Research Communications, 1996, 226, 158-165.	1.0	29
390	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncology Reports, 0, , .	1.2	15
391	Anticancer Activity of Oldenlandia Diffusa & Viola Philippica Car. Journal of Cancer Research Updates, 0, , .	0.3	2
392	Vemurafenib (PLX4032, ZelborafÂ®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance. Journal of Cancer Research Updates, 0, , .	0.3	0
393	B5H7, a Morpholine Derivative of 23-Hydroxybetulinic Acid, Reverses Doxorubicin Resistance in HepG2/ADM. Journal of Cancer Research Updates, 0, , .	0.3	0
394	Editorial: Chemo-Radiation-Resistance in Cancer Therapy. Frontiers in Pharmacology, 0, 13, .	1.6	7
395	The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms. Frontiers in Oncology, 0, 12, .	1.3	1